Gene Disease Score gda Association Type Original DB Sentence supporting the association PMID PMID Year
Entrez Id: 2064
Gene Symbol: ERBB2
ERBB2
CUI: C0024623
Disease: Malignant neoplasm of stomach
Malignant neoplasm of stomach
0.700 AlteredExpression BEFREE HER2 over-expression was detected in 23 out of 49 (46.9%) patients with intestinal GC, and 9 out of 35 (25.7%) patients with diffuse GC. 22654433

2012

Entrez Id: 2064
Gene Symbol: ERBB2
ERBB2
CUI: C0024623
Disease: Malignant neoplasm of stomach
Malignant neoplasm of stomach
0.700 Biomarker BEFREE Physical basis of the 'magnification rule' for standardized Immunohistochemical scoring of HER2 in breast and gastric cancer. 29530054

2018

Entrez Id: 2064
Gene Symbol: ERBB2
ERBB2
CUI: C0024623
Disease: Malignant neoplasm of stomach
Malignant neoplasm of stomach
0.700 Biomarker BEFREE Trastuzumab in combination with chemotherapy is the standard of care for patients with human epidermal growth factor receptor 2 (HER2)-positive breast and gastric cancers. 28223426

2017

Entrez Id: 2064
Gene Symbol: ERBB2
ERBB2
CUI: C0024623
Disease: Malignant neoplasm of stomach
Malignant neoplasm of stomach
0.700 Biomarker BEFREE Notably, the addition of trastuzumab to first-line chemotherapy has improved the overall survival of patients with HER2-positive gastric cancer, and has become the standard-of-care treatment for this group of patients. 31548601

2020

Entrez Id: 2064
Gene Symbol: ERBB2
ERBB2
CUI: C0024623
Disease: Malignant neoplasm of stomach
Malignant neoplasm of stomach
0.700 Biomarker BEFREE Using anti-HER2/neu antibody and the proposed HER2/neu scoring system for gastric cancer, HER2/neu IHC expression was recorded after manual scoring and automated IA interpretation. 22646266

2012

Entrez Id: 2064
Gene Symbol: ERBB2
ERBB2
CUI: C0024623
Disease: Malignant neoplasm of stomach
Malignant neoplasm of stomach
0.700 Biomarker BEFREE Combination of trastuzumab with cytotoxic chemotherapy has demonstrated a survival advantage in patients with Her2/Neu positive gastric cancer. 23288635

2013

Entrez Id: 2064
Gene Symbol: ERBB2
ERBB2
CUI: C0024623
Disease: Malignant neoplasm of stomach
Malignant neoplasm of stomach
0.700 Biomarker BEFREE This experiment investigated the suppressive role of miR-3622b-5p in ERBB2-positive breast and gastric cancers. 28160563

2017

Entrez Id: 2064
Gene Symbol: ERBB2
ERBB2
CUI: C0024623
Disease: Malignant neoplasm of stomach
Malignant neoplasm of stomach
0.700 AlteredExpression BEFREE Altogether, NCI-N87 cell line constitutes an appealing in vitro model to address glycan-mediated regulation of ErbB2 in GC. 29143776

2017

Entrez Id: 2064
Gene Symbol: ERBB2
ERBB2
CUI: C0024623
Disease: Malignant neoplasm of stomach
Malignant neoplasm of stomach
0.700 Biomarker BEFREE Gene amplification and protein overexpression of the growth factor receptors c-erbB2 and K-sam may be prognostic factors for intestinal- and diffuse-type gastric cancer, respectively. 11525306

2000

Entrez Id: 2064
Gene Symbol: ERBB2
ERBB2
CUI: C0024623
Disease: Malignant neoplasm of stomach
Malignant neoplasm of stomach
0.700 AlteredExpression BEFREE HER2 overexpression/amplification is linked to trastuzumab response in breast/gastric cancers. 26690310

2016

Entrez Id: 2064
Gene Symbol: ERBB2
ERBB2
CUI: C0024623
Disease: Malignant neoplasm of stomach
Malignant neoplasm of stomach
0.700 Biomarker BEFREE HER2-ECD (human epidermal growth factor receptor 2 - extracellular domain) is a prominent therapeutic target validated for treating HER2-positive breast and gastric cancer, but HER2-specific therapeutic options for treating advanced gastric cancer remain limited. 30365359

2019

Entrez Id: 2064
Gene Symbol: ERBB2
ERBB2
CUI: C0024623
Disease: Malignant neoplasm of stomach
Malignant neoplasm of stomach
0.700 Biomarker BEFREE Therefore, oxaliplatin-Au-Fe<sub>3</sub>O<sub>4</sub>-Herceptin is a promising multifunctional platform for simultaneous magnetic traceable and HER2 targeted chemotherapy for gastric cancer. 29731915

2018

Entrez Id: 2064
Gene Symbol: ERBB2
ERBB2
CUI: C0024623
Disease: Malignant neoplasm of stomach
Malignant neoplasm of stomach
0.700 Biomarker BEFREE GC patients (n = 237), including a subset from the Trastuzumab in GC (ToGA) trial were divided into three groups based on HER2 status and history of treatment with standard chemotherapy or chemotherapy plus trastuzumab. 27687309

2017

Entrez Id: 2064
Gene Symbol: ERBB2
ERBB2
CUI: C0024623
Disease: Malignant neoplasm of stomach
Malignant neoplasm of stomach
0.700 Biomarker BEFREE Trastuzumab is currently used for patients with Her2(+) advanced gastric cancer. 23630346

2013

Entrez Id: 2064
Gene Symbol: ERBB2
ERBB2
CUI: C0024623
Disease: Malignant neoplasm of stomach
Malignant neoplasm of stomach
0.700 Biomarker BEFREE HER2 Genetic Heterogeneity in Gastric Cancer: Evaluation According to the College of American Pathologists Breast Cancer Criteria. 25611242

2015

Entrez Id: 2064
Gene Symbol: ERBB2
ERBB2
CUI: C0024623
Disease: Malignant neoplasm of stomach
Malignant neoplasm of stomach
0.700 Biomarker BEFREE Unlike in breast and gastric cancer, currently there are no established guidelines for HER2 testing in endometrial carcinoma. 23765245

2013

Entrez Id: 2064
Gene Symbol: ERBB2
ERBB2
CUI: C0024623
Disease: Malignant neoplasm of stomach
Malignant neoplasm of stomach
0.700 AlteredExpression BEFREE HER2 overexpression is associated with metastasis-the main cause of death in individuals with gastric cancer. 20460098

2010

Entrez Id: 2064
Gene Symbol: ERBB2
ERBB2
CUI: C0024623
Disease: Malignant neoplasm of stomach
Malignant neoplasm of stomach
0.700 Biomarker BEFREE Phase II study of trastuzumab in combination with S-1 plus cisplatin in HER2-positive gastric cancer (HERBIS-1). 24473399

2014

Entrez Id: 2064
Gene Symbol: ERBB2
ERBB2
CUI: C0024623
Disease: Malignant neoplasm of stomach
Malignant neoplasm of stomach
0.700 Biomarker BEFREE The treatment of patients with human epidermal growth factor receptor 2 (HER2)-negative gastric cancer is a major challenge. 31423245

2019

Entrez Id: 2064
Gene Symbol: ERBB2
ERBB2
CUI: C0024623
Disease: Malignant neoplasm of stomach
Malignant neoplasm of stomach
0.700 AlteredExpression BEFREE Since intratumoral HER2 heterogeneity is also an important issue, a multicenter large-scale study was conducted to evaluate the prognostic impacts of HER2 expression and intratumoral heterogeneity in gastric cancer. 25224659

2015

Entrez Id: 2064
Gene Symbol: ERBB2
ERBB2
CUI: C0024623
Disease: Malignant neoplasm of stomach
Malignant neoplasm of stomach
0.700 Biomarker BEFREE The HER2 gene is known to play an important role in the oncogenesis of several types of cancers, such as breast, ovarian, colon and gastric cancers. 14618618

2004

Entrez Id: 2064
Gene Symbol: ERBB2
ERBB2
CUI: C0024623
Disease: Malignant neoplasm of stomach
Malignant neoplasm of stomach
0.700 Biomarker BEFREE Aside from the human epidermal growth factor receptor-2 (HER2)-targeting agent trastuzumab, molecular targeting therapy for gastric cancer (GC) has not been established. 23110662

2012

Entrez Id: 2064
Gene Symbol: ERBB2
ERBB2
CUI: C0024623
Disease: Malignant neoplasm of stomach
Malignant neoplasm of stomach
0.700 Biomarker BEFREE Correction to: Phase II study to evaluate the efficacy of Trastuzumab in combination with Capecitabine and Oxaliplatin in first-line treatment of HER2-positive advanced gastric cancer: HERXO trial. 31587095

2019

Entrez Id: 2064
Gene Symbol: ERBB2
ERBB2
CUI: C0024623
Disease: Malignant neoplasm of stomach
Malignant neoplasm of stomach
0.700 Biomarker BEFREE The most relevant new agent in gastric cancer therapy is trastuzumab for HER2-positive gastric carcinomas. 21896085

2011

Entrez Id: 2064
Gene Symbol: ERBB2
ERBB2
CUI: C0024623
Disease: Malignant neoplasm of stomach
Malignant neoplasm of stomach
0.700 Biomarker BEFREE HER2/neu amplification is associated with response to HER2/neu-directed therapy in breast and gastric cancers. 26022204

2015